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Introduction: Chronic obstructive pulmonary disease (COPD) is a complex and
heterogeneous respiratory disease with important extra-pulmonary features
and comorbidities. The aim of this study was to assess clinical heterogeneity in a
well-defined subgroup of individuals with COPD GOLD D, including possible gender
differences.
Methods: Pulmonary function, arterial blood gases, exercise performance, quadriceps
muscle function, problematic activities of daily life, dyspnea, health status and comor-
bidities have been assessed in 117 individuals with a MRC dyspnea grade 4/5 and COPD
GOLD D entering pulmonary rehabilitation.
Results: A broad range of values were found for diffusion capacity, exercise capacity,
quadriceps muscle function and health status. Indeed, the high coefficients of variation
were found for these outcomes. Problematic activities of daily life as well as objectified
comorbidities also varied to a great extent. Moreover, significant gender differences
were found for exercise performance, lower-limb muscle function and various
comorbidities.-horn.nl (M.J.H. Sillen).
3 Elsevier Ltd. All rights reserved.
13.04.020
Heterogeneity in individuals with COPD GOLD D 1187Conclusion: The current findings emphasize that COPD is a heterogeneous disease whose
clinical presentation varies significantly, even in individuals with very severe COPD with
the same degree of dyspnea and all classified as GOLD D.
Trial registration: NTR2322.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is an
important cause of morbidity, disability-adjusted life years
and mortality worldwide.1 Generally, a significant hetero-
geneity in symptoms, clinical characteristics and comor-
bidities exist in patients with COPD.2e7 Besides the
degree of airflow limitation, symptoms, exacerbations and
comorbidities contribute to the overall severity in patients
with COPD.7e9 The latest GOLD document stratifies patients
into four groups (i.e., A to D) based on a combined
assessment, including the degree of airflow limitation,
future exacerbation risk and the burden of disease.9
The Medical Research Council (MRC) scale is a simple,
readily available office tool to grade dyspnea.10 In the latest
GOLD document, the modified MRC has been used to
determine the burden of disease.9 Generally, clinical char-
acteristics and extra-pulmonary features of COPD are
different after stratification for MRC dyspnea grade.11e14
For example, COPD patients with MRC dyspnea grades 4/5
have an increased risk for ischemic electrocardiographic
changes,14 worse exercise performance, higher scores for
anxiety and depression and worse disease-specific health
status12 as compared to those with lower MRC dyspnea
grades. Moreover, during domestic activities of daily life
COPD patients with MRC dyspnea grades 4 or 5 use a signif-
icantly higher proportion of their peak aerobic capacity and
ventilation accompanied with higher task-related dyspnea
scores.13 So, MRC dyspnea grades 4/5 provide a rough indi-
cation of the clinical status of patients with COPD. However,
anecdotal clinical experience suggests that COPD is a com-
plex, heterogeneous disease whose clinical presentation
varies significantly despite having the same degree of dys-
pnea. Moreover, multiple studies have found that women
with COPD report higher (Zworse) scores on the MRC dys-
pnea scale than men with COPD for the same degree of
airflow limitation.15e17 This suggests that individuals with
COPD GOLD D will have a heterogeneous clinical presenta-
tion, despite belonging to the same GOLD group.
Therefore, we sought to characterize the heterogeneity
of individuals with COPD with GOLD D, including possible
gender differences.Methods
Patients and setting
Individuals with COPD who were referred by their chest
physician for an interdisciplinary pulmonary rehabilitation
program at CIROþ were recruited.18 Individuals with COPD
as the primary diagnosis8 and a MRC dyspnea grade 4 or 5
were eligible.19 As these are the baseline findings of theDICES trial (Dyspneic Individuals with COPD: Electrical
stimulation or Strength training), participants also needed
to have quadriceps weakness, defined as a peak torque
80% of the predicted value.20 Individuals with known
neuromuscular diseases; hip, leg and/or knee disorders
including metal implants; cardiac pacemaker and/or in-
ternal cardiac defibrillator were ineligible. The Medical
Ethical Committee of the Maastricht University Medical
Centreþ (MEC 09-3-072) approved this study, which con-
formed to the principles outlined in the World Medical As-
sociation declaration of Helsinki which was revised in
Seoul.21 Details of the trial were registered at www.
trialregister.nl (NTR2322) before subject enrollment. All
patients gave written informed consent to participate.
Assessments
Medical history
During the medical history, the number of patient-reported
COPD exacerbations in the 12 months prior to assessment,
the usage of long-term oxygen therapy (LTOT) and all res-
piratory and non-respiratory medications prescribed by
secondary care respiratory physicians were routinely
recorded.22
Pulmonary function and arterial blood gases
Post-bronchodilator forced expiratory volume in one sec-
ond (FEV1) and forced vital capacity (FVC) were determined
using spirometry (MasterScreen Body, Carefusion, Houten,
the Netherlands). Diffusing capacity for carbon monoxide
(DLCO) was determined using the single breath method. All
values were related to reference values.23 Arterial oxygen
tension (PaO2), arterial carbon dioxide tension (PaCO2)
were measured with a blood gas analyzer (GEM4000,
Instrumentation Laboratory, Peachtree City, USA).
Exercise performance
A supervised symptom-limited cardiopulmonary incremen-
tal cycle test on an electrically, braked cycle ergometer
(Carefusion, Houten, the Netherlands) was conducted, as
described before.24 Peak aerobic capacity (only in subjects
without oxygen supplement, n Z 55) and peak work rate
were determined. A constant work-rate cycling endurance
test was performed at 75% of the peak work rate.25 Func-
tional exercise capacity was measured using the six-minute
walk test, which was performed twice.26 The best 6-
min walk distance (6MWD) was used for further analyses.
Quadriceps muscle function
Quadriceps muscle function (peak strength and endurance)
was measured using a Biodex (Biodex System 4 Pro, Biodex
Medical Systems, Inc., New York, USA).24 The reliability of
this method in patients with COPD has been demonstrated
1188 M.J.H. Sillen et al.previously.27 Peak muscle strength (Newtonmeter; Nm) and
muscle endurance (Total work; TW) were measured iso-
kinetically. The participants performed thirty volitional
maximal contractions at an angular velocity of 90 per
second. The measurement was performed twice, and best
values were used for further analyses.
Problematic activities of daily life
The COPM, a semi-structured interview, was used to assess
problematic activities of daily life (ADLs).28 Problematic
ADLs were categorized into four domains: self-care, pro-
ductivity, leisure and mobility.11
Dyspnea and health status
The Medical Research Council (MRC) dyspnea scale was
used to assess symptoms of dyspnea.19 Health status was
measured with the St. George’s Respiratory Questionnaire
(SGRQ).29 Scores can range from 0 (optimal) to 100 points
(worst).
Comorbidities
The degree of self-reported comorbidities was measured
using the Charlson comorbidity index.30 Moreover, the
following comorbidities were objectified, as described
before7:
Body composition abnormalities
Body mass index (BMI, defined as body weight divided by
squared height) and fat-free mass index ((FFMI), defined as
fat free mass divided by squared height) were determined,
and classified as obesity (BMI  30 kg/m2), underweight
(BMI < 21 kg/m2), and/or muscle wasting (FFMI < 14.62 kg/
m2 in women and FFMI <17.05 kg/m2 in men).31 In addition,
bone mineral density (BMD of the hip, lumbar spine and
whole body region, expressed as T-scores) were determined
using dual-energy X-ray absorptiometry.32 If the lowest of
the three T-scores was <2.5, the subject was defined as
osteoporotic.33
Symptoms of anxiety and depression
Symptoms of anxiety and depression were measured using
the Hospital Anxiety and Depression Scale (HADS).34 Scores
can range from 0 (optimal) to 21 points (worst). A score of
10 points or more was defined as increased symptoms of
anxiety and/or depression.3,34
Hyperglycemia, anemia, dyslipidemia and systemic
inflammation
Routinely, a post-absorptive venous blood sample was
collected from the patients in the fasted state to analyze
glucose, hemoglobin, triglycerides, high density lipoprotein
(HDL) and creatinine.
A fasting glucose level >5.6 mmol/L was defined as hy-
perglycemia35; anemia was defined as a hemoglobin level
<13 g/dL (8.1 mmol/L, men) or <12 g/dL (7.5 mmol/L,
women)36; dyslipidemia was defined as a triglyceride level
above 1.7 mmol/L or a HDL cholesterol level below
1.03 mmol/L (men) or below 1.29 mmol/L (women).37Renal impairment
Renal function was established by the estimated glomerular
filtration rate (eGFR), using the Cockroft-Gault formula.38
Chronic kidney disease was defined as eGFR <60 ml/min,
corresponding with stage 3 chronic kidney disease accord-
ing to the National Kidney Foundation Kidney Disease
Outcome Quality Initiative (NKF KDOQI) guidelines.39
Cardiovascular abnormalities
Peripheral blood pressure was measured three times with
interval of 5 min, after 15 min of supine rest in early
morning time. Mean values were calculated. Hypertension
grade 1 or higher was based on cut-off values of
>140 mmHg for systolic blood pressure and >90 mmHg for
diastolic blood pressure.40
A resting ECG was obtained and the Cardiac Infarction
Injury Score (CIIS) was scored by a cardiologist (NHMKU-L)
blinded for medical history and outcomemeasures. CIIS is an
ECG classification system that was developed as a diagnostic
tool to determine the presence of myocardial infarctions.
It is based on the power of certain electrocardiographic
characteristics to discriminate between myocardial infarc-
tion patients and healthy individuals. These characteristics
are weighted and combined into a single score.41 Myocardial
infarction was defined as a CIIS 20.41
Statistical analysis
All statistical analyses were performed using SPSS for Win-
dows, Version 17.0.1 (SPSS, Inc., Chicago, Il, USA) and
GraphPad Prism Version 4.03 (GraphPad Software, Inc., La
Jolla, USA). Data were presented as mean  standard de-
viation, as median and interquartile range, or as fre-
quencies, as appropriate. Gender differences were
assessed using the Student’s t-test, c2 test or Man-
neWhitney U test. We additionally used the coefficient of
variation (the ratio of the standard deviation to the mean)
to present the degree of variability. A priori, the level of
significance was set at <0.05.
Results
Characteristics of whole sample
In total, 120 individuals with COPD fulfilled all inclusion
criteria and consented to participate in the DICES trial.
Nevertheless, three individuals with COPD GOLD B were
excluded from the current analysis to focus specifically on
individuals with GOLD D.
The remaining 117 individuals with GOLD D had severe
to very severe COPD and an impaired diffusion capacity
(Table 1). 52% of the patients used long-term oxygen
therapy and 72% patients reported 1 or more exacerbations
in the previous 12 months (Fig. 1). Various types of respi-
ratory and non-respiratory medications were used (Table 1
of the Online-Supplement). On average, participants had a
decreased exercise capacity (Table 2), lower-limb muscle
dysfunction (Table 3), and a decreased health status (SGRQ
Table 1 General characteristics.
Total sample
n Z 117
Men
n Z 61
Women
n Z 56
P-value
Age years 64.7  8.1 (0.13) 66.7  8.3 62.6  7.5 0.005
FEV1 liters 0.84  0.34 (0.40) 0.94  0.38 0.72  0.26 <0.000
FEV1 %predicted 33  13 (0.39) 31  13 34  13 0.254
FEV1/VC max % 31  11 (0.35) 30  12 33  9 0.139
DLCO %predicted 41  15 (0.37) 41  16 41  14 0.997
RV % 201  53 (0.26) 198  58 204  47 0.537
PaO2 kPa 9.7  1.6 (0.16) 9.9  1.7 9.4  1.5 0.079
PaCO2 kPa 5.7  1.2 (0.21) 5.5  1.2 5.9  1.2 0.108
SaO2 % 95  2 (0.02) 96  2 95  3 0.111
LTOT % 52 48 57 0.301
Values expressed as mean  SD (coefficient of variation) or percentages.
Abbreviations: GOLD Z Global Initiative on Obstructive Lung Diseases; LTOT Z long-term oxygen therapy; FEV1 Z forced expiratory
volume in one second; VC max Z maximum vital capacity; DLCO Z diffusion capacity of the lung for carbon monoxide; RV Z residual
volume; PaO2Z resting arterial oxygen tension; PaCO2Z resting arterial carbon dioxide tension; SaO2Z resting arterial oxygen tension;
kPa Z kilopascal.
Heterogeneity in individuals with COPD GOLD D 1189total score: 63.8  13.2 points). Even though all partici-
pants reported a MRC dyspnea grade of 4/5 and GOLD D, the
clinical characteristics showed a broad range of values
(Fig. 2AeE). Indeed, peak work rate ranged from 4 to 68 W;
the 6-min walk distance ranged from 22 to 544 m; health
status ranged from 22 to 88 points; anxiety scores ranged
from 1 to 19 points; and depression scores ranged from 1 to
18 points. Moreover, the coefficient of variation ranged
from 0.52 for bone mineral density to 0.49 for cycle
endurance time and HADS anxiety score. Moreover, 42
problematic activities of daily were reported, with walking,
showering, and household activities as the most prevalent
(see Online Supplement Tables 2 and 3 for all details).
Finally, 87% of the participants scored 1 objectified
comorbidities (Charlson comorbidity index score:
1.57  0.82 points). Hyperglycaemia, low muscle mass, and
symptoms of anxiety were most prevalent (Table 4; Fig. 3).
Men versus women
The degree of airflow limitation (% predicted), DLCO and
arterial blood gases were similar between men and women0
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Figure 1 Number of exacerbations in the past 12 months.(Table 1). Peak work load and peak VO2 (after correction
for lower-limb muscle mass) and 6MWD expressed (% pre-
dicted) were significantly higher in women compared to
men (all p < 0.05; Table 2). The performance and satis-
faction scores for self-reported problematic ADLs on the
COPM were similar between men and women (3.5  1.7
versus 3.5  1.9 points; and 3.0  1.8 versus 3.1  2.1
points, respectively). Women reported walking, household
activities and showering to be to the most important
problematic ADLs, while men reported walking, showering
and stair climbing. Disease-specific health status (SGRQ
total score: 65.0  12.1 versus 62.6  14.3 points,
respectively), BMI and bone mineral density were not
different between men and women (Table 3). Women had
significantly higher symptom scores of anxiety (pZ 0.024),
and a higher proportion of obesity, dyslipidemia and renal
impairment (Fig. 3).
Discussion
The current findings emphasize that COPD is a heteroge-
neous disease whose clinical presentation varies signifi-
cantly, even in individuals with very severe COPD with the
same degree of dyspnea and all classified as GOLD D.
Moreover, significant gender differences were found for
exercise performance, lower-limb muscle function and
various comorbidities.
Previously, heterogeneity in clinical outcomes has been
found after stratification for GOLD stage II to IV, suggesting
that the degree of airflow limitation does not capture the
clinical heterogeneity of COPD.5,42 The current study shows
a broad heterogeneity in exercise capacity, lower-limb
muscle function, mood status, health status, exacerba-
tions and comorbidities in individuals with COPD GOLD D
and MRC dyspnea grade 4/5. The coefficient of variation for
various clinical characteristics (i.e., FEV1: 0.33 versus 0.39;
6MWD: 0.33 versus 0.31; and BMI: 0.22 versus 0.205) seems
comparable between the 2007 GOLD classification (based
solely on degree of airflow limitation)8 and the 2013 GOLD
classification.43 This suggests that the MRC dyspnea scale as
Table 2 Exercise performance.
Cardiopulmonary exercise test Total Men Women P-value
n Z 101 n Z 53 n Z 48
Peak load Watts 44  13 (0.30) 48  10 41  14 0.006
Peak load/FFM Watts/kg 0.96  0.28 (0.29) 0.90  0.21 1.03  0.33 0.024
Peak VO2 ml/min 820  159 (0.19) 834  153 802  168 0.467
Peak VO2/FFM ml/min/kg 17.8  4.0 (0.22) 16.0  2.8 20.3  4.0 <0.001
Constant work rate test n Z 93 n Z 51 n Z 42
Cycle time seconds 192  95 (0.49) 199  108 184  76 0.468
6 min walk test n Z 117 n Z 61 n Z 56
6MWD meters 322  92 (0.29) 314  87 331  97 0.321
6MWD <350 m % 56 62 48 0.127
6MWD %predicted 52  16 (0.31) 47  14 57  17 0.002
Values expressed as mean  SD (coefficient of variation) or percentages.
Abbreviations: peak VO2 Z peak oxygen uptake in ml/min.; peak VE Z peak minute ventilation in liters; peak HR Z peak heart rate;
bpm Z beats per minute; %MVV Z percentage maximal voluntary ventilation; tSaO2 Z transcutaneous oxygen saturation; 6MWD Z 6-
min walk distance; kg Z kilogram; min Z minute; ml Z milliliter.
1190 M.J.H. Sillen et al.well as the new GOLD classification may provide clinicians
with a global impression of the clinical status of patients
with COPD. However, patients with COPD need to be
assessed individually to be able to provide a patient-
tailored comprehensive COPD management program.
Therefore, it seems reasonable to state that the new GOLD
classification9 cannot be the basis for personalized COPD
management. The variability in clinical characteristics and
comorbidities in this group of individuals with COPD GOLD D
may partially explain the odds of survival in this sub-
group.44,45 Obviously, this needs to be corroborated
prospectively.
Multimorbidity occurs frequently in the general popula-
tion.46 Comorbidities occur also frequently in patients with
COPD entering pulmonary rehabilitation.7,48 Comparable
frequencies of comorbidities have been found in the cur-
rent study (Fig. 3). This emphasizes again the complexity of
patients with COPD entering pulmonary rehabilitation. For
example, patients with COPD with increased symptoms ofTable 3 Body composition and muscle function.
Body composition Total
n Z 117
BMI kg/m2 24.7  5.0 (0.20
FFMI kg/m2 16.5  2.0 (0.12
Bone mineral density T-score 2.1  1.1 (0.5
Isokinetic quadriceps muscle function n Z 117
Peak torque Nm 76.0  26.4 (0.35
Peak torque %predicted 54  16 (0.30
Peak torque/FFM Nm/kg 1.6  0.5 (0.31
Total work Joules 1175  480 (0.41
Total work/FFM Joules/kg 25.2  8.9 (0.35
Values expressed as mean  SD (coefficient of variation).
Abbreviations: BMI Z body mass index; FFM Z fat-free mass; FFMI
Nm Z newtonmeter.anxiety and/or depression have worse prognosis.49,50
Moreover, individuals with COPD who also had osteopo-
rosis at baseline had worst response on the 6-min walk test
following pulmonary rehabilitation.51
Even though the degree of dyspnea, the degree of
airflow limitation and the new GOLD group were similar
between women and men in the present study, still signif-
icant gender differences were found. The female patients
had a better exercise performance compared to men, after
adjustment for FFM (Table 2). Even though the women were
significantly younger (mean difference: 3 years), this does
not seem to explain the mean difference in peak aerobic
capacity (4.3 ml/min/kg FFM; 27%). Whether and to what
extent this difference is due to changes in muscle structure
and function, neurological function,52 cardiovascular
function,53 hormonal exposures, health behaviors54 or a
combination thereof remains to be determined.
Women had a higher prevalence of obesity, anxiety,
dyslipidemia and renal impairment. This suggests thatMen Women P-value
n Z 61 n Z 56
) 24.1  4.7 25.3  5.2 0.217
) 17.4  1.9 15.5  1.6 <0.001
2) 2.0  1.3 2.1  0.9 0.656
n Z 61 n Z 56
) 86.6  27.7 64.5  19.3 <0.001
) 51  16 57  16 0.075
) 1.6  0.5 1.6  0.5 0.810
) 1308  542 1029  353 0.001
) 24.7  9.4 25.9  8.3 0.468
Z fat-free mass index; kg Z kilogram; m2 Z squared meter;
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Figure 2 Heterogeneity in clinical characteristics. The distribution is shown for men (circles) and women (squares). The median
is shown with a black line. A: Wpeak (peak work rate); B: 6MWD (6-min walk test); C: SGRQ (health status); D: HADS anxiety;
E: HADS depression.
Heterogeneity in individuals with COPD GOLD D 1191gender-specific patterns of comorbidities may exist in
COPD. Whether and to what extent gender-differences in
comorbidities may contribute to the overall severity of
COPD patients remains to be determined. At first sight,
health status does not seem to be influenced by these dif-
ferences as mean SGRQ scores were similar between
women and men in the present study.Table 4 Mood and health status.
HADS Total
n Z 110
Anxiety points 8.9  4.4 (0.49
Anxiety 10 points % 38
Depression points 8.4  3.8 (0.45
Depression 10 points % 32
SGRQ n Z 109
Symptoms points 66.3  16.9 (0.25)
Activity points 81.7  16.4 (0.20)
Impact points 53.1  17.5 (0.33)
Total score points 63.9  13.2 (0.21)
Values expressed as mean  SD (coefficient of variation) or percenta
Abbreviations: HADS Z Hospital Anxiety and Depression Scale; SGRQObviously, the inclusion criteria of the DICES trial limits
the external validity of the present findings. Nevertheless,
previous studies have already shown a large heterogeneity in
clinical outcomes, like 6MWD, after stratification for MRC
dyspnea grade or GOLD stage.5,12 Therefore, the authors
believe that theheterogeneous clinical presentation ofCOPD
is not limited to individuals with MRC 4/5 and COPD GOLD D.Men Women P-value
n Z 57 n Z 53
) 8.0  4.0 9.9  4.6 0.024
25 52 0.003
) 8.1  3.5 8.6  4.2 0.497
31 34 0.749
n Z 55 n Z 54
66.5  16.3 66.2  17.7 0.939
83.3  16.4 80.1  16.4 0.321
54.3  15.8 51.9  19.2 0.477
65.0  12.0 62.8  14.3 0.388
ges.
Z St. George’s Respiratory Questionnaire.
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Figure 3 Prevalence of objectified comorbidities.
1192 M.J.H. Sillen et al.To conclude, COPD patients with severe dyspnea and
classified as high risk with more symptoms according to the
new GOLD classification have a highly variable clinical
presentation. Moreover, this heterogeneity remains after
stratification for sex. Finally, clinically relevant gender-
differences exist, although the degree of dyspnea and the
degree of airflow limitation were comparable between
women and men. These findings emphasize that patients
with COPD entering a pulmonary rehabilitation program
need to be assessed interdisciplinary and individually to be
able to provide a patient-tailored program. Moreover, the
new GOLD classification seems inappropriate to capture the
clinical heterogeneity of patients with COPD.
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